COVID-19 Supplements: Elovanoids From Omega-3 Found To Block SARS-CoV-2 Cell Entry And Protects Lung Cells.
: A new study led by researchers from Louisiana State University along with scientists from Tulane University School of Medicine and the University Of Southern California has found that Elovanoids made from omega-3 fatty acids may block the SARS-CoV-2 coronavirus that causes COVID-19 from entering cells and protect the air cells (alveoli) of the lung.
Elovanoids which were discovered in 2017 in the laboratory of Nicolas Bazan, MD, Ph.D., at Louisiana State University are the first bioactive chemical messengers made from omega-3
very long chain polyunsaturated fatty acid (VLC-PUFAs,n-3) that are released in response to cell injury or when cells are confronted with adversities for survival.
The study findings found that the pro-homeostatic lipid mediators elovanoids (ELVs) attenuate cell binding and entrance of the SARS-CoV-2 receptor-binding domain (RBD) as well as of the SARS-CoV-2 virus in human primary alveoli cells in culture.
The study team uncovered that very-long-chain polyunsaturated fatty acid precursors (VLC-PUFA, n-3) activate ELV biosynthesis in lung cells. Both ELVs and their precursors reduce the binding to RBD. ELVs downregulate angiotensin-converting enzyme 2 (ACE2) and enhance the expression of a set of protective proteins hindering cell surface virus binding and upregulating defensive proteins against lung damage. In addition, ELVs and their precursors decreased the signal of spike (S) protein found in SARS-CoV-2 infected cells, suggesting that the lipids curb viral infection.
These study findings open avenues for potential preventive and disease-modifiable therapeutic approaches for COVID-19.
The study findings were published in the peer reviewed journal: Scientific Reports. https://www.nature.com/articles/s41598-021-91794-z
Dr Nicolas Bazan, MD, Ph.D., Director of the LSU Health New Orleans Neuroscience Center and senior author of the paper told Thailand Medical News, "Because the compounds are protective against damage in the brain and retina of the eye and the COVID-19 virus clearly damages the lung, the experiment tested if the compounds would also protect the lung."
The study team tested Elovanoids (ELVs) on infected lung tissue from a 78-year-old man in petri dish cultures. The team found that ELVs not only reduced the ability of the SARS-CoV-2 spike protein to bind to receptors and enter cells, but they also triggered the production of protective, anti-inflammatory proteins that counteract lung damage.
The researchers report that ELVs decreased the production of ACE2. ACE2 is a protein on the surface of many cell types. ACE2 receptors act like locks on cells, and the SARS-CoV-2 spike proteins act like keys that open the locks letting the virus enter cells to multiply rapidly.
The study team also demonstrated for the first time that alveolar cells are endowed with pathways for the biosynthesis of ELVs.
Dr Bazan further added, "Since SARS-CoV-2 affects nasal mucosa, the GI tract, the eye, and the nervous system,
uncovering the protective potential of ELVs expands the scope of our observations beyond the lungs. Our results provide a foundation for interventions to modify disease risk, progression, and protection of the lung from COVID-19 or other pathologies (including some types of pneumonia)."
Please help to donate to sustain this website and also all our research initiatives. Your contribution helps saves lives. https://www.thailandmedical.news/p/sponsorship
For the latest on COVID-19 Supplements
, keep on logging to Thailand Medical News.